Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Acquired by Fjarde AP Fonden Fourth Swedish National Pension Fund

Fjarde AP Fonden Fourth Swedish National Pension Fund raised its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 17.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 34,447 shares of the medical equipment provider’s stock after purchasing an additional 5,000 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Zimmer Biomet were worth $3,639,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Stonebridge Financial Group LLC acquired a new stake in shares of Zimmer Biomet during the 4th quarter worth $25,000. Dunhill Financial LLC grew its position in Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 218 shares during the period. Ashton Thomas Securities LLC acquired a new stake in Zimmer Biomet during the third quarter worth about $28,000. Brooklyn Investment Group purchased a new position in shares of Zimmer Biomet in the 3rd quarter worth about $35,000. Finally, Kentucky Trust Co acquired a new position in shares of Zimmer Biomet in the 4th quarter valued at about $39,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Up 1.5 %

Shares of NYSE:ZBH opened at $107.54 on Wednesday. The firm has a market cap of $21.41 billion, a PE ratio of 24.17, a price-to-earnings-growth ratio of 1.95 and a beta of 1.02. The company has a fifty day simple moving average of $105.83 and a 200 day simple moving average of $107.44. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a 12-month low of $97.69 and a 12-month high of $133.90.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the prior year, the company posted $2.20 earnings per share. On average, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.89%. The ex-dividend date of this dividend was Monday, December 30th. Zimmer Biomet’s dividend payout ratio is presently 21.57%.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on ZBH shares. JMP Securities reissued a “market outperform” rating and set a $140.00 target price on shares of Zimmer Biomet in a research report on Friday, February 7th. Stifel Nicolaus increased their price objective on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research report on Thursday, January 23rd. Wells Fargo & Company lifted their target price on shares of Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Raymond James lowered their price target on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a report on Friday, February 7th. Finally, JPMorgan Chase & Co. upgraded Zimmer Biomet from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $125.00 to $128.00 in a research note on Tuesday, December 17th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $124.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.